15 June 2023 | Thursday | News
Image Source : Public Domain
"The initiation of our FIH clinical trial with MDR-001 is an important milestone for MindRank which is yet another great validation of the potential of our AI platform," said Zhangming Niu, CEO of MindRank. "The company is committed to advancing the clinical development of MDR-001 globally in order to make this therapy available to patients as soon as possible."
This FIH Phase 1 study is a randomized, double-blind, placebo-controlled, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of MDR-001 in healthy volunteers and patients with obesity or T2DM.
MDR-001 is a novel, β-arrestin 2 selective, orally bioavailable small-molecule GLP-1 RA discovered using MindRank's proprietary AI platform, Molecule Pro. MDR-001 has been tested comprehensively in preclinical studies and demonstrated excellent functional potency and selectivity, with favorable ADME properties and oral bioavailability, as well as desirable pharmacokinetics, safety and tolerability, indicating its best-in-class potential for the treatment of obesity and T2DM with large unmet medical needs.